Search research articles
Contact Us
Filters
Showing results (111-120 of 116) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 116 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Kathryn A Haynes, Zackery A Cope, Sean-Paul Gerard Williams, et al.
Biorxiv : the Preprint Server for Biology
|
June 29, 2026
Molecular mechanisms underlying amyloid lowering by aducanumab: differential and comparative effects of sex and IgG reveal the post-treatment disease brain
K A Haynes, R S Pandey, E H Doud, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
August 26, 2022
Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL-AD preclinical testing core study
Kristen D Onos, Sara K Quinney, David R Jones, et al.
Frontiers in Aging Neuroscience
|
August 9, 2021
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study
Adrian L Oblak, Peter B Lin, Kevin P Kotredes, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
July 18, 2022
Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice
Adrian L Oblak, Zackary A Cope, Sara K Quinney, et al.
Eclinicalmedicine
|
December 9, 2022
Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosis
Theresia A Mikolasch, Peter M George, Jagdeep Sahota, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 116) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 116 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Kathryn A Haynes, Zackery A Cope, Sean-Paul Gerard Williams, et al.
Biorxiv : the Preprint Server for Biology
|
June 29, 2026
Molecular mechanisms underlying amyloid lowering by aducanumab: differential and comparative effects of sex and IgG reveal the post-treatment disease brain
K A Haynes, R S Pandey, E H Doud, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
August 26, 2022
Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL-AD preclinical testing core study
Kristen D Onos, Sara K Quinney, David R Jones, et al.
Frontiers in Aging Neuroscience
|
August 9, 2021
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study
Adrian L Oblak, Peter B Lin, Kevin P Kotredes, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
July 18, 2022
Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice
Adrian L Oblak, Zackary A Cope, Sara K Quinney, et al.
Eclinicalmedicine
|
December 9, 2022
Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosis
Theresia A Mikolasch, Peter M George, Jagdeep Sahota, et al.
Page
of 12